Your session is about to expire
← Back to Search
Thiazolidinedione
Troglitazone in Treating Patients With Liposarcoma
Phase 2
Waitlist Available
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
Eligible Conditions
- Soft Tissue Sarcoma
- Sarcoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2010 Phase 2 trial • 246 Patients • NCT0106886011%
Hypoglycaemia
7%
Tremor
4%
Hyperhidrosis
4%
Nausea
4%
Dysphonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo + Metforimin + Sulfonylurea
Placebo + Insulin
Canakinumab 150 mg + Insulin
Canakinumab 150 mg in Patients With IGT
Canakinumab 150 mg + Metforimin + Sulfonylurea
Placebo + Met + Sulfonyl + Thiazolidinedione
Placebo + Metformin
Canakinumab 150 mg + Metformin
Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione
Placebo in Patients With IGT
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: TroglitazoneExperimental Treatment1 Intervention
Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Troglitazone
FDA approved
Find a Location
Who is running the clinical trial?
Dana-Farber Cancer InstituteLead Sponsor
1,113 Previous Clinical Trials
358,796 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,956 Previous Clinical Trials
41,112,012 Total Patients Enrolled
George D. Demetri, MDStudy ChairDana-Farber Cancer Institute
6 Previous Clinical Trials
438 Total Patients Enrolled